Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Queensland Health
Cantor Fitzgerald
Citi
Julphar
Covington
Accenture
Novartis
Moodys
US Army

Generated: January 20, 2018

DrugPatentWatch Database Preview

ASTRAZENECA Company Profile

« Back to Dashboard

What is the competitive landscape for ASTRAZENECA, and what generic alternatives to ASTRAZENECA drugs are available?

ASTRAZENECA has ninety-four approved drugs.

There are one hundred and forty-four US patents protecting ASTRAZENECA drugs and there have been four Paragraph IV challenges on ASTRAZENECA drugs in the past three years.

There are two thousand six hundred and seventy-two patent family members on ASTRAZENECA drugs in seventy-four countries and one hundred and ninety-nine supplementary protection certificates in sixteen countries.

Summary for ASTRAZENECA
International Patents:2672
US Patents:144
Tradenames:68
Ingredients:58
NDAs:94

Drugs and US Patents for ASTRAZENECA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-006 Oct 4, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Ab BYDUREON BCISE exenatide SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 209210-001 Oct 20, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Ab FARXIGA dapagliflozin propanediol TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms NEXIUM esomeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 021957-004 Dec 15, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-002 Sep 26, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Ab FARXIGA dapagliflozin propanediol TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Ab KOMBIGLYZE XR metformin hydrochloride; saxagliptin hydrochloride TABLET, EXTENDED RELEASE;ORAL 200678-003 Nov 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Ab BYETTA exenatide synthetic INJECTABLE;SUBCUTANEOUS 021773-001 Apr 28, 2005 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca METAPROTERENOL SULFATE metaproterenol sulfate SOLUTION;INHALATION 071275-001 Jul 27, 1988 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca PLENDIL felodipine TABLET, EXTENDED RELEASE;ORAL 019834-004 Sep 22, 1994 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ASTRAZENECA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca NOLVADEX tamoxifen citrate TABLET;ORAL 017970-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms NEXIUM IV esomeprazole sodium INJECTABLE;INTRAVENOUS 021689-002 Mar 31, 2005 ➤ Subscribe ➤ Subscribe
Astrazeneca LEXXEL enalapril maleate; felodipine TABLET, EXTENDED RELEASE;ORAL 020668-001 Dec 27, 1996 ➤ Subscribe ➤ Subscribe
Astrazeneca ATACAND candesartan cilexetil TABLET;ORAL 020838-002 Jun 4, 1998 ➤ Subscribe ➤ Subscribe
Astrazeneca ATACAND candesartan cilexetil TABLET;ORAL 020838-003 Jun 4, 1998 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms PRILOSEC OTC omeprazole magnesium TABLET, DELAYED RELEASE;ORAL 021229-001 Jun 20, 2003 ➤ Subscribe ➤ Subscribe
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-001 Mar 16, 2005 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms NEXIUM esomeprazole magnesium CAPSULE, DELAYED REL PELLETS;ORAL 021153-001 Feb 20, 2001 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms PRILOSEC omeprazole CAPSULE, DELAYED REL PELLETS;ORAL 019810-002 Jan 15, 1998 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms NEXIUM esomeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 021957-003 Dec 15, 2011 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ASTRAZENECA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Nasal Spray 2.5 mg/spray ➤ Subscribe 6/9/2016
➤ Subscribe Tablets 60 mg ➤ Subscribe 9/30/2015
➤ Subscribe Tablets 90 mg ➤ Subscribe 7/20/2015
➤ Subscribe Tablets 500 mcg ➤ Subscribe 3/2/2015
➤ Subscribe Injection 250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe ➤ Subscribe 6/11/2014
➤ Subscribe Nasal Spray 5 mg/spray ➤ Subscribe 11/14/2013
➤ Subscribe Extended-release Tablets 5 mg/500 mg, 2.5 mg/1000 mg, and 5 mg/1000 mg ➤ Subscribe 7/31/2013
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 7/31/2013
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 3/30/2012
➤ Subscribe Nasal Spray 250 mcg ➤ Subscribe 2/13/2012
➤ Subscribe Inhalation Suspension 1 mg/2 mL ➤ Subscribe 5/28/2010
➤ Subscribe For Injection 20 mg/vial and 40 mg/vial ➤ Subscribe 11/23/2009
➤ Subscribe Injection 50 mg/mL, 2.5 mL and 5 mL syringe ➤ Subscribe 10/1/2009
➤ Subscribe Tablets 32 mg/25 mg ➤ Subscribe 3/6/2009
➤ Subscribe Extended-release Tablets 150 mg ➤ Subscribe 11/17/2008
➤ Subscribe Extended-release Tablets 50 mg ➤ Subscribe 10/17/2008
➤ Subscribe Tablets 16 mg/12.5 mg and 32 mg/12.5 mg ➤ Subscribe 6/25/2008
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 6/18/2008
➤ Subscribe Tablets 200 mg and 300 mg ➤ Subscribe 6/12/2008
➤ Subscribe Nasal Spray 0.032 mg (32 mcg)/spray ➤ Subscribe 5/14/2007
➤ Subscribe Delayed-release Capsules 20 mg ➤ Subscribe 3/19/2007
➤ Subscribe Tablets 50 mg, 150 mg and 400 mg ➤ Subscribe 2/12/2007
➤ Subscribe Tablets 4 mg, 8 mg, 16 mg and 32 mg ➤ Subscribe 12/22/2006
➤ Subscribe Tablets 100 mg, 200 mg and 300 mg ➤ Subscribe 2/21/2006
➤ Subscribe Inhalation Suspension 0.25 mg/2 mL and 0.5 mg/2 mL ➤ Subscribe 9/15/2005
➤ Subscribe Tablets 25 mg ➤ Subscribe 8/12/2005
➤ Subscribe Delayed-release 20 mg and 40 mg ➤ Subscribe 8/5/2005

Non-Orange Book US Patents for ASTRAZENECA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,149,539 Crystalline naloxol-PEG conjugate ➤ Subscribe
7,750,006 Phthalazinone derivatives ➤ Subscribe
7,692,006 Phthalazinone derivatives ➤ Subscribe
9,453,039 Crystal structures of SGLT2 inhibitors and processes for preparing same ➤ Subscribe
7,799,345 Preparation of injectable suspensions having improved injectability ➤ Subscribe
7,220,721 Exendin agonist peptides ➤ Subscribe
7,875,310 Residual solvent extraction method and microparticles produced thereby ➤ Subscribe
7,700,549 Exendin agonist analogs to treat diabetes ➤ Subscribe
8,349,307 Polymer conjugates of opioid antagonists ➤ Subscribe
8,802,699 Quinuclidine derivatives and medicinal compositions containing the same ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ASTRAZENECA Drugs

Supplementary Protection Certificates for ASTRAZENECA Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C022/2005 Ireland ➤ Subscribe SPC022/2005, 20060612, EXPIRES: 20190415
90009-9 Sweden ➤ Subscribe PRODUCT NAME: TICAGRELOR ELLER ETT FARMACEUTISKT ACCEPTABELT SALT DAERAV; REG. NO/DATE: EU/1/10/655/001-006 20101203
0677 Netherlands ➤ Subscribe PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
0048 Netherlands ➤ Subscribe PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
C005/2010 Ireland ➤ Subscribe SPC005/2010: 20100702, EXPIRES: 20240930
1998 Austria ➤ Subscribe PRODUCT NAME: CANDESARTAN CILEXETIL ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: 1-22232, 1-22233, 1-22235, 1-22236 19971119; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
/2015 Austria ➤ Subscribe PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
7 Finland ➤ Subscribe
0150012 00136 Estonia ➤ Subscribe PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
12/048 Ireland ➤ Subscribe PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
Medtronic
McKinsey
Citi
Fuji
Deloitte
Healthtrust
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot